MedPage Today on MSN
Gene therapy-induced CAR T cells for myeloma could alter treatment landscape
ORLANDO -- A gene therapy that could transform CAR T-cell treatment achieved rapid and potentially durable measurable ...
In multiple myeloma, plasma cells proliferate uncontrollably in the bone marrow, disrupting the growth of healthy ...
An in vivo chimeric antigen receptor T-cell therapy administered without lymphodepletion exhibited activity among patients with advanced multiple myeloma, according to findings presented at ASH Annual ...
Kelonia Therapeutics' KLN-1010 has shown promising early results in a phase 1 trial for relapsed or refractory multiple ...
Serious side effects, including neurotoxicity and intestinal inflammation, that appear weeks or months after patients receive ...
News Medical on MSN
Serious side effects after CAR T cell therapy for multiple myeloma share a common immune root cause
Serious side effects, including neurotoxicity and intestinal inflammation, that appear weeks or months after patients receive CAR T cell therapy for multiple myeloma share a common immune root cause, ...
A proposed combination of Johnson & Johnson’s multiple myeloma bispecific Tecvayli has turned up positive trial data that ...
CAR-T cell therapy faces accessibility challenges, primarily available at large urban centers, leading to geographic and socioeconomic disparities. The KarMMa-3 study showed Abecma CAR-T therapy ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Jonathan L.
The global CAR T-Cell Therapy for Multiple Myeloma market is experiencing transformative growth, driven by advances in BCMA-targeted therapies like FDA-approved Abecma and Carvykti. These treatments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback